This is my first "podcast" episode ever (assuming that if it's just me talking into a microphone, it's still considered a podcast). In it, I discuss exactly how AI is going to revolutionize cancer therapy by telling a story about one of the first immunotherapy ever, cytokines.

How is AI going to revolutionize immunotherapy? A story about cytokines.

CAR technology is going to have to undergo rapid evolution if it expects to compete in today's oncology market. In this podcast episode, Jeff Martin (Founder at Oncoleader) explains how Universal CAR technology might be the hero come to rescue CARs from extinction.

Episode 2 - Why "Universal CARs" are going to be the future of CAR technology

Recent evidence suggests that CAR-T cells can be used to, potentially, cure autoimmune disorders. However, are we sure we need to use T cells to achieve these results. After all, there are several therapeutic limitations of T cell therapies that may be overcome if we were to use another cell type. In this episode, I make the case for NK cells as a the cell type of choice for cell therapy against autoimmunity.

Making the Case for Natural Killer Cells in Autoimmunity

In this episode, Dr. Jeff Martin dissects the role of macrophages in tumor initiation and progression and then discusses the various ways that researchers are leveraging macrophage function to treat cancer.

Making the Case for Natural Killer Cells in Autoimmunity

Oncoleader

Related tracks